Prognostic role of the reduced folate carrier, the major membrane transporter for methotrexate, in childhood acute lymphoblastic leukemia: A report from the children's oncology group

Clinical Cancer Research

Volumn 13, Issue 2 I, 2007, Pages 451-457

  Ge, Yubin ^a   Haska, Christina L ^a   LaFiura, Katherine ^a   Devidas, Meenakshi ^c   Linda, Stephen B ^c   Liu, Mingjun ^a   Thomas, Ronald ^b   Taub, Jeffrey W ^a,b   Matherly, Larry H ^a,d  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d KARMANOS CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; REDUCED FOLATE CARRIER; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CASE CONTROL STUDY; CHILD; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; RANK SUM TEST; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; TRANSCRIPTION REGULATION; TREATMENT OUTCOME; VALIDATION PROCESS;

ADOLESCENT; ANTIMETABOLITES, ANTINEOPLASTIC; BIOLOGICAL TRANSPORT; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; MEMBRANE TRANSPORT PROTEINS; METHOTREXATE; PROGNOSIS; RECURRENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 33846879411     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2145     Document Type: Article

References (36)

1. Farber S, Diamond LK, Mercer RD, et al. Temporary remissions in acute leukemia in children produced by the folic acid antagonist, 4-aminopteroyl glutamaic acid (aminopterin). N Engl J Med 1948;238:787-93.
2. Kersey JH. Fifty years of studies of the biology and therapy of childhood leukemia. Blood 1997;90:4243.
3. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006;354:166-78.
4. Moos PJ, Raetz EA, Carlson MA, et al. Identification of gene expression profiles that segregate patients with childhood leukemia. Clin Cancer Res 2002;8:3118-30.
5. Yeoh EJ, Ross ME, Shurtleff SA, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002;1:133-43.
6. Holleman A, Cheok MH, den Boer ML, et al. Gene expression patterns in drug resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 2004;351:533-42.
7. Cario G, Stanulla M, Fine BM, et al. Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukema. Blood 2005;105:821-6.
8. Lugthart S, Cheok MH, den Boer ML, et al. Identification of genes associated with chemotherapy cross resistance and treatment response in childhood acute lymphoblastic leukemia. Cancer Cell 2005;7:375-86.
9. Kato GJ, Quddus FF, Shuster JJ, et al. High glucocorticoid receptor content of leukemic blasts is a favorable prognostic factor in childhood acute lymphoblastic leukemia. Blood 1993;82:2304-9.
10. den Boer ML, Pieters R, Kazemier KM, et al. Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia. Blood 1998;91:2092-8.
11. Dhooge C, De Moerloose B, Laureys G, et al. P-glycoprotein is an independent prognostic factor predicting relapse in childhood acute lymphoblastic leukemia: results of a 6 year prospective study. Br J Haematol 1999;105:676-83.
12. Sauerbrey A, Sell W, Steinbach D, et al. Expression of the BCRP gene (ABCG2/MXR/ABCP) in childhood acute lymphoblastic leukemia. Br J Haematol 2002;118:147-50.
13. Levy AS, Sather HN, Steinherz PG, et al. Reduced folate carrier and dihydrofolate reductase expression in acute lymphoblastic leukemia may predict outcome: a Children's Cancer Group study. J Pediatr Hematol Oncol 2003;25:688-95.
14. Steinbach D, Wittig S, Cario G, et al. The multidrug resistance- associated protein 3 (MRP3) is associated with a poor outcome in childhood ALL and may acount for the worse prognosis in male patients and T-cell immunophenotvpe. Blood 2003;102:4493-8.
15. Fine BM, Kaspers GJL, Ho M, et al. A genome-wide view of the in vitro response to L-asparaginase in acute lymphoblastic leukemia. Cancer Res 2005;65:291-9.
16. Guerin E, Entz-Werle N, Eyer D, et al. Modification of topoisomerase genes copy number in newly diagnosed childhood acute lymphoblastic leukemia. Leukemia 2003;17:532-40.
17. Kager L, Cheok M, Yang W, et al. Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. J Clin Invest 2005;115:110-7.
18. Holleman A, de Boer ML, Menezes RX, et al. The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia. Blood 2005;107:769-76.
19. Plasschaert SLA, de Bont ESJM, Boezen M, et al. Expression of multidrug resistance-associated proteins predicts prognosis in childhood and adult acute lymphoblastic leukemia. Clin Cancer Res 2005;11:8661-8.
20. Gorlick R, Goker E, Trippett T, et al. Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med 1996;335:1041-8.
21. Shah SJ, Taub JW, Witt TL, et al. Relationship of p15 and p16 gene alterations to elevated dihydrofolate reductase in childhood acute lymphoblastic leukemia. Br J Haematol 2001;113:746-6.
22. Flatley RM, Payton SG, Taub JW, Matherly LH. Primary acute lymphoblastic leukemia cells use a novel promoter and 5′non-coding exon for the human reduced folate carrier that encodes a modified carrier translated from an upstream translational start. Clin Cancer Res 2004;10:5111-22.
23. Liu M, Ge Y, Payton SG, et al. Transcriptional regulation of the human reduced folate carrier in childhood acute lymphoblastic leukemia cells. Clin Cancer Res 2006;12:608-16.
24. SAS Institute, Inc. SAS OnlineDoc® 9.1.3. Cary (NC): SAS Institute, Inc.; 2005.
25. R Development CoreTeam. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL. Available from: http://www.R-project.org. 2005.
26. Margolin JF, Poplack DG. Acute lymphoblastic leukemia. In: Pizza PA, Poplack DG, editors. Principles and practice of pediatric oncology. Philadelphia (PA): J.B. Lippincott Co.; 1997.
27. Whitehead VM, Shuster JJ, Vuchich MJ, et al. Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts and treatment outcome in children with B-progenitor-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Leukemia 2005;19:533-6.
28. Barredo JC, Synold TW, Laver J, et al. Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia. Blood 1994;84:564-9.
29. Galpin AJ, Schuetz JD, Masson E, et al. Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity. Mol Pharmacol 1997;52:155-63.
30. Schuetz JD, Matherly LH, Westin EH, Goldman ID. Evidence for a functional defect in the translocation of the methotrexate transport carrier in a methotrexate resistant murine L1210 leukemia cell line. J Biol Chem 1988;263:9840-7.
31. Jansen G, Mauritz R, Drori S, et al. A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. J Biol Chem 1998;273:30189-98.
32. Sirotnak FM, Moccio DM, Kelleher LE, Goutas LJ. Relative frequency and kinetic properties of transport-defective phenotypes among methotrexate resistant L1210 clonal cell lines derived in vivo. Cancer Res 1981;41:4447-52.
33. Guo W, Healey JH, Meyers PA, et al. Mechanisms of methotrexate resistance in osteosarcoma. Clin Can Res 1999;5:621-7.
34. Zhang L, Taub JW, Williamson M, et al. Reduced folate carrier gene expression in childhood acute lymphoblastic leukemia: relationship to immunophenotype and ploidy. Clin Can Res 1998;4:2169-77.
35. Payton SG, Haska CL, Flatley RM, Ge Y, Matherly LH. Effects of 5′ untranslated region diversity on the posttranslational regulation of the human reduced folate carrier. Biochim Biophys Acta. In press.
36. Goldman ID, Matherly LH. The cellular pharmacology of methotrexate. Pharmacol Ther 1985;28:77-100.